BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bordeaux Neurocampus - ECPv4.9.10//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bordeaux Neurocampus
X-ORIGINAL-URL:https://www.bordeaux-neurocampus.fr/en/
X-WR-CALDESC:Events for Bordeaux Neurocampus
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20210708T100000
DTEND;TZID=Europe/Paris:20210708T100000
DTSTAMP:20260308T161412
CREATED:20210430T103043Z
LAST-MODIFIED:20210616T112039Z
UID:134216-1625738400-1625738400@www.bordeaux-neurocampus.fr
SUMMARY:Thesis defense - Frédéric Villéga
DESCRIPTION:\n	\n		\n			\n Via zoom : https://u-bordeaux-fr.zoom.us/j/82043365426 \n\nDefense in english\nTitle: Molecular impact of the antagonist ketamine in Auto-immune encephalitis with NMDAR-Ab \nAbstract\nAmong autoimmune encephalitis\, the discovery of autoantibodies directed against the glutamatergic NMDA receptor (NMDAR-Ab)\, in the so-called anti-NMDAR encephalitis\, has shed new lights on how neurological and psychiatric features can be directly related to NMDAR dysfunction. In particular\, it emerged that NMDAR-Ab profoundly alter the receptor membrane dynamics and content without affecting per se its ionotropic transmission (no antagonistic action). Because the therapeutic removal of NMDAR-Ab in anti-NMDAR encephalitis patients takes time and some neuropsychiatric features remains well after treatment\, the search for complementary drugs that would prevent the deleterious effect of NMDAR-Ab is of great interest. Using a unique combination of single molecule\, FRAP\, and FRET imaging\, immunocytochemical\, and behavioural approaches\, we here demonstrate that the non-competitive NMDAR antagonist ketamine is also potent regulator of the receptor surface dynamics\, stabilizing synaptic NMDARs. Ketamine prevents synaptic and behavioural deficits induced by NMDAR-Ab from anti-NMDAR encephalitis patients. This action was not due to the blockade of the ionotropic transmission since a competitive antagonist was fully ineffective. Instead\, ketamine alters NMDAR conformation\, favoring its synaptic anchoring and preventing receptor dispersal by autoantibodies. Thus\, we unveil a non-canonical action of the clinically-relevant ketamine on the NMDAR trafficking\, opening new avenues of research and therapeutical use. \nKeywords: NMDAR-Encephalitis\, NMDAR\, auto-antibodies\, Ketamine \nJury\nPatrick Blanco\, President\nPierre Gressens\, Judge\nJosep Dalmau\, Judge\nAna Luísa Carvalho\, Referee\nJérome Honnorat\, Referee \n\n		\n	\n\n	\n		\n			 \nFrédéric Villéga\nTeam Groc\nIINS \nThesis surpervisor: Laurent Groc \n\n		\n	\n\n
URL:https://www.bordeaux-neurocampus.fr/en/event/thesis-defense-frederic-villega/
CATEGORIES:Thesis
END:VEVENT
END:VCALENDAR